Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) Equity Average (2020 - 2025)

Historic Equity Average for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Q3 2025 value amounting to $804.1 million.

  • Harmony Biosciences Holdings' Equity Average rose 4164.36% to $804.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $804.1 million, marking a year-over-year increase of 4164.36%. This contributed to the annual value of $563.1 million for FY2024, which is 2946.75% up from last year.
  • Per Harmony Biosciences Holdings' latest filing, its Equity Average stood at $804.1 million for Q3 2025, which was up 4164.36% from $746.8 million recorded in Q2 2025.
  • Harmony Biosciences Holdings' 5-year Equity Average high stood at $804.1 million for Q3 2025, and its period low was $102.5 million during Q1 2021.
  • In the last 5 years, Harmony Biosciences Holdings' Equity Average had a median value of $464.1 million in 2023 and averaged $417.2 million.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 12058.11% in 2022, then skyrocketed by 1354.9% in 2024.
  • Over the past 5 years, Harmony Biosciences Holdings' Equity Average (Quarter) stood at $169.3 million in 2021, then skyrocketed by 120.58% to $373.4 million in 2022, then grew by 27.0% to $474.2 million in 2023, then skyrocketed by 32.44% to $628.0 million in 2024, then increased by 28.05% to $804.1 million in 2025.
  • Its Equity Average was $804.1 million in Q3 2025, compared to $746.8 million in Q2 2025 and $689.8 million in Q1 2025.